Metformin with neoadjuvant chemotherapy in localized triple‐negative and Her2neu‐positive breast cancer: A prospective phase 2 open‐label randomized controlled trial (McBETH)
Metformin did not significantly improve pCR when added to standard NACT. However, trends in HER2-positive patients and reduced neuropathy merit further investigation.
Authors
- Mouna Bellakhdher
- Sandeep Mathur (ORCID: https://orcid.org/0000-0002-6729-6833)
- Akash Kumar (ORCID: https://orcid.org/0000-0003-3978-0879)
- Ajay Gogia (ORCID: https://orcid.org/0000-0001-6500-1061)
- Supriya Mallick (ORCID: https://orcid.org/0000-0003-4228-5211)
- Ashish Datt Upadhyay (ORCID: https://orcid.org/0000-0002-5957-5429)
- Babita Kataria (ORCID: https://orcid.org/0000-0002-3708-8363)
- Jyoutishman Saikia (ORCID: https://orcid.org/0000-0002-3567-6292)
- Ashutosh Mishra (ORCID: https://orcid.org/0000-0002-5390-5482)
- Atul Batra (ORCID: https://orcid.org/0000-0002-1934-8408)
- Simran Kaur (ORCID: https://orcid.org/0000-0001-9091-9480)
- Aparna Sharma (ORCID: https://orcid.org/0000-0002-7369-2007)
- Jyoti Sharma (ORCID: https://orcid.org/0000-0001-9811-2139)
- Atul Sharma (ORCID: https://orcid.org/0000-0002-8960-5449)
- Rajesh Khadgawat
- Suryanarayana Deo
- Dayanand Sharma (ORCID: https://orcid.org/0000-0002-2138-2218)
Institutions
- All India Institute of Medical Sciences Bhubaneswar (IN)
- All India Institute of Medical Sciences (IN)
Publication Details
- Journal
- Cancer
- Published
- 2025-12-05
- DOI
- https://doi.org/10.1002/cncr.70205
- Primary Topic
- Metabolism, Diabetes, and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00